DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; June 2009 (2009-06), ROBAK TADEUSZ: "GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.", Database accession no. NLM19513948 (B1)

FLUGE ÒOYSTEIN ET AL: "Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series", BMC NEUROLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 9, no. 1, 1 July 2009 (2009-07-01), page 28, XP021057466, ISSN: 1471-2377, DOI: 10.1186/1471-2377-9-28 (B1)

ØYSTEIN FLUGE ET AL: "Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study", PLOS ONE, vol. 6, no. 10, 19 October 2011 (2011-10-19), page e26358, XP055092685, DOI: 10.1371/journal.pone.0026358 (B1)

LUNDELL KATHLEEN ET AL: "Clinical activity of folinic acid in patients with chronic fatigue syndrome" ARZNEIMITTEL-FORSCHUNG, vol. 56, no. 6, 2006, pages 399-404, XP001539327 ISSN: 0004-4172 (B1)

ROBERTSON ET AL.: "Lyphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression" CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 141, 2005, pages 326-332, XP002481553 (B1)

KLIMAS N G ET AL: "IMMUNOLOGIC ABNORMALITIES IN CHRONIC FATIGUE SYNDROME" JOURNAL OF CLINICAL MICROBIOLOGY, vol. 28, no. 6, 1990, pages 1403-1410, XP002481552 ISSN: 0095-1137 (B1)